Nabriva Therapeutics plc (NASDAQ:NBRV – Get Rating)’s stock price hit a new 52-week low during mid-day trading on Monday . The stock traded as low as $3.28 and last traded at $3.28, with a volume of 35825 shares changing hands. The stock had previously closed at $3.82.
Analyst Ratings Changes
Separately, StockNews.com assumed coverage on shares of Nabriva Therapeutics in a research note on Monday. They set a “hold” rating on the stock.
Nabriva Therapeutics Trading Down 6.3 %
The company has a debt-to-equity ratio of 0.01, a current ratio of 2.81 and a quick ratio of 2.01. The company has a fifty day moving average of $6.31 and a 200-day moving average of $6.99. The firm has a market capitalization of $75.06 million, a PE ratio of -0.13 and a beta of 1.46.
Hedge Funds Weigh In On Nabriva Therapeutics
Several institutional investors have recently bought and sold shares of NBRV. Frazier Life Sciences Management L.P. bought a new position in Nabriva Therapeutics during the first quarter valued at about $179,000. Renaissance Technologies LLC grew its position in shares of Nabriva Therapeutics by 102.1% in the second quarter. Renaissance Technologies LLC now owns 795,938 shares of the biotechnology company’s stock valued at $145,000 after purchasing an additional 402,144 shares during the last quarter. Finally, GSA Capital Partners LLP acquired a new stake in shares of Nabriva Therapeutics in the fourth quarter valued at about $214,000. 0.53% of the stock is currently owned by institutional investors.
About Nabriva Therapeutics
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia.
- Get a free copy of the StockNews.com research report on Nabriva Therapeutics (NBRV)
- 3 Airline Stocks Stuck in a Holding Pattern
- Roku Stock is Down but Not Out
- Is Ford Rolling To A Rebound After Its Q3 Warning
- If You’re Hungry for Value, Take a Bite on Ruth’s Hospitality Grp
- Has AMD stock stock fallen too far?
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.